Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

被引：0
|
作者：
Davide Melisi
Rocio Garcia-Carbonero
Teresa Macarulla
Denis Pezet
Gael Deplanque
Martin Fuchs
Jorg Trojan
Helmut Oettle
Mark Kozloff
Ann Cleverly
Claire Smith
Shawn T. Estrem
Ivelina Gueorguieva
Michael M. F. Lahn
Al Blunt
Karim A. Benhadji
Josep Tabernero
机构：
[1] University of Verona,Oncology Department
[2] Piazzale Ludovico Antonio Scuro,undefined
[3] Hospital Universitario 12 de Octubre,undefined
[4] Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12),undefined
[5] UCM,undefined
[6] CNIO,undefined
[7] CIBERONC,undefined
[8] Vall d’Hebron University Hospital Institute of Oncology (VHIO),undefined
[9] CIBERONC,undefined
[10] C/ Natzaret,undefined
[11] 115-117,undefined
[12] Centre Hospitalier Universitaire,undefined
[13] Hôpital Riviera-Chablais,undefined
[14] Klinikum Bogenhausen,undefined
[15] Städtisches Klinikum München GmbH,undefined
[16] Goethe University Medical Center,undefined
[17] Onkologische und Hämatologische Schwerpunktpraxis,undefined
[18] Ingalls Memorial Hospital,undefined
[19] Eli Lilly and Company,undefined
[20] Erl Wood Manor,undefined
[21] Windlesham,undefined
[22] formerly of Eli Lilly and Company,undefined
[23] Eli Lilly and Company,undefined
[24] Lilly Corporate Center,undefined
[25] 6820 Wisconsin Ave.,undefined
[26] #8008,undefined
[27] Advaxis,undefined
[28] Inc.,undefined
[29] Eli Lilly and Company,undefined
[30] Vall d’Hebron University Hospital and Institute of Oncology (VHIO),undefined
[31] CIBERONC,undefined
[32] Universitat Autònoma de Barcelona,undefined
[33] P. Vall d’Hebron 119-129,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1208 / 1214
页数：6
相关论文
共 50 条
  • [31] A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib plus gemcitabine (GG) or gemcitabine plus placebo (GP) in patients with unresectable pancreatic cancer (PC)
    Melisi, Davide
    Garcia-Carbonero, Rocio
    Macarulla, Teresa
    Pezet, Denis
    Deplanque, Gael
    Fuchs, Martin
    Trojan, Joerg
    Oettle, Helmut
    Kozloff, Mark
    Cleverly, Ann
    Gueorguieva, Ivelina
    Desaiah, Durisala
    Lahn, Michael M.
    Al Blunt
    Benhadji, Karim A.
    Tabernero, Josep
    CANCER RESEARCH, 2016, 76
  • [32] Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
    Petrioli, Roberto
    Torre, Pamela
    Pesola, Guido
    Paganini, Giovanni
    Paolelli, Loretta
    Miano, Salvatora Tindara
    Martellucci, Ignazio
    Francini, Guido
    Francini, Edoardo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (04) : 647 - 651
  • [33] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J. Cohen
    Mark M. Zalupski
    Manuel R. Modiano
    Paul Conkling
    Yehuda Z. Patt
    Peg Davis
    Robert T. Dorr
    Michelle L. Boytim
    Evan M. Hersh
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 287 - 294
  • [34] Gemcitabine Plus Irinotecan as First-Line Weekly Therapy in Locally Advanced and/or Metastatic Pancreatic Cancer
    Neri, B.
    Cipriani, G.
    Grifoni, R.
    Molinara, E.
    Pantaleo, P.
    Rangan, S.
    Vannini, A.
    Tonelli, P.
    Valeri, A.
    Pantalone, D.
    Taddei, A.
    Bechi, P.
    ONCOLOGY RESEARCH, 2009, 17 (11-12) : 559 - 564
  • [35] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Cohen, Steven J.
    Zalupski, Mark M.
    Modiano, Manuel R.
    Conkling, Paul
    Patt, Yehuda Z.
    Davis, Peg
    Dorr, Robert T.
    Boytim, Michelle L.
    Hersh, Evan M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 287 - 294
  • [36] First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (18) : 4022 - 4033
  • [37] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Junko Tahara
    Kyoko Shimizu
    Nao Otsuka
    Junichi Akao
    Yukiko Takayama
    Katsutoshi Tokushige
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 245 - 250
  • [38] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [39] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Guo, Jhe-Cyuan
    Yang, Shih-Hung
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 634 - 642
  • [40] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Jhe-Cyuan Guo
    Shih-Hung Yang
    International Journal of Clinical Oncology, 2014, 19 : 634 - 642
12345